글로벌 결절성 가려움증 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

결절성 양진 시장 분석

결절성 가려움증 시장은 가려움증 결절증의 유병률 증가와 피부 질환에 대한 인식 제고로 인해 상당한 성장을 경험하고 있습니다. 가려운 결절이 특징인 이 만성 피부 질환은 종종 상당한 불편함을 유발하고 환자의 삶의 질에 영향을 미칩니다. 시장의 최근 발전에는 증상을 완화하고 환자 결과를 개선하는 것을 목표로 하는 혁신적인 치료 옵션이 포함됩니다. 예를 들어, 단일 클론 항체 및 생물학적 제제와 같은 새로운 치료법은 가려움증 결절증의 근본적인 메커니즘을 보다 효과적으로 타겟팅하기 위해 탐구되고 있습니다. 시장 참여자들은 또한 R&D 지출을 늘리고 치료 접근성을 개선하기 위해 의료 전문가와 협력하는 데 주력하고 있습니다. 전반적으로 결절성 가려움증 시장은 연구 및 제품 혁신의 발전이 계속해서 나타나 이 어려운 질환으로 고통받는 환자의 요구를 충족시키면서 성장할 준비가 되어 있습니다.

결절성 가려움증 시장 규모

글로벌 결절성 가려움증 시장 규모는 2023년에 12억 2천만 달러로 평가되었으며, 2031년까지 192억 7천만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 5.80%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

결절성 가려움증 시장 동향

“ 표적 생물학적 치료법의 개발 증가”

결절성 가려움증 시장은 피부 질환에 대한 인식 증가와 결절성 가려움증 유병률 증가에 힘입어 주목할 만한 성장을 보이고 있습니다. 시장을 형성하는 중요한 추세 중 하나는 증상을 완화하는 것보다 질환의 근본 원인을 해결하는 것을 목표로 하는 표적 생물학적 치료법의 개발입니다. 기업들은 이러한 진보된 치료법을 탐구하기 위해 연구 개발에 투자하고 있으며, 이는 피부과 에서 개인화된 의학으로의 전환을 반영합니다 . 또한 의료 서비스 제공자가 만성 피부 질환의 심리적 영향을 점점 더 인식함에 따라 신체적, 정서적 웰빙을 모두 포괄하는 포괄적인 치료 접근 방식에 대한 강조가 커지고 있습니다. 이러한 추세는 환자 결과를 향상시키고 보다 효과적인 치료 옵션이 제공됨에 따라 결절성 가려움증 시장의 추가 성장을 촉진할 것으로 예상됩니다.

보고 범위 및 결절성 가려움증 시장 세분화     

결절성 양진 시장 정의

결절성 가려움증은 피부에 심하게 가려운 결절이 생기는 만성 피부 질환입니다. 이러한 결절은 일반적으로 팔, 다리, 몸통에 나타나며 알레르기나 곤충 물림과 같은 질환과 관련된 비정상적인 면역 반응으로 인해 발생합니다. 심한 가려움증은 긁는 것으로 이어질 수 있으며, 이는 병변을 더욱 악화시키고 피부 손상을 일으킬 수 있습니다. 이 질환은 불편함과 2차 감염 가능성으로 인해 환자의 삶의 질에 상당한 영향을 미칠 수 있습니다.

결절성 Prurigo 시장 역학

운전자

• 만성 가려움증의 유병률 증가

The rising prevalence of chronic pruritus conditions serves as a significant market driver for the global nodular prurigo sector. Chronic pruritus, characterized by persistent itching, impacts millions worldwide and can severely diminish quality of life. According to the JAMA, approximately 22% of the population experiences chronic itching at some point, with conditions like atopic dermatitis, psoriasis, and nodular prurigo contributing to this statistic. As the population ages and the incidence of skin disorders rises, the demand for nodular prurigo treatments is expected to grow, directly influencing the expansion of the nodular prurigo market. This increasing recognition of chronic pruritus’s debilitating effects is driving investments in innovative therapies, ultimately boosting market growth and fostering the development of targeted treatments for nodular prurigo.

• Rising Global Aging Population

The aging global population is a significant factor driving the demand for therapies to treat skin disorders, including prurigo nodularis. Older adults are more prone to skin conditions due to factors like thinning skin, reduced immune function, and chronic health issues. According to the World Health Organization (WHO), the global population aged 60 years and older is expected to reach 2.1 billion by 2050, nearly doubling from 1 billion in 2020. Such demographic shift is associated with an increased prevalence of age-related skin disorders, such as prurigo nodularis and other chronic pruritus conditions. Studies show that individuals over 65 years old experience some form of chronic itching, significantly raising the demand for effective dermatological treatments and contributing to the growth of the nodular prurigo market.

Opportunities

• Growing Awareness among Healthcare Professionals and Patients

Growing awareness among healthcare professionals and patients about nodular prurigo as a distinct and serious condition is creating significant market opportunities. Historically, nodular prurigo was often misdiagnosed or treated as a generalized pruritus condition, leading to inadequate management. However, recent advances in medical understanding, along with increased efforts by healthcare organizations to educate both physicians and the public, are leading to earlier and more accurate diagnosis. For instance, the launch of educational initiatives like the International Forum for the Study of Itch (IFSI) has been pivotal in raising awareness about chronic pruritus conditions, including nodular prurigo. Such shift is expanding the patient pool eligible for targeted treatments, driving demand for specialized therapies designed specifically for nodular prurigo. As awareness continues to rise, pharmaceutical companies have the opportunity to develop and market innovative treatments, ensuring they meet the growing demand and address the unmet needs of this patient population.

• Growing Advancements in Therapies

Advances in therapies, particularly innovations in monoclonal antibodies like nemolizumab, present significant growth potential in the prurigo nodularis market. These targeted therapies are specifically designed to address the underlying mechanisms of the condition, offering more effective and tailored treatment options compared to traditional approaches. Nemolizumab, for instance, is a first-in-class monoclonal antibody that blocks interleukin-31 (IL-31) signaling, a key pathway involved in the chronic itching and inflammation associated with prurigo nodularis. The growing focus on developing such biologic treatments is expanding therapeutic options, paving the way for more personalized care. As these therapies gain regulatory approvals and enter the market, they are expected to capture substantial market share, particularly in addressing the unmet needs of patients who have not responded to conventional treatments, ultimately creating opportunities in the market.

Restraints/Challenges

• Treatment Assosiated Side Effects

The existing treatments for nodular prurigo, including corticosteroids and immunosuppressants, are associated with a range of significant side effects that can limit their long-term usability. Patients may experience complications such as weight gain, increased susceptibility to infections, and adrenal suppression, leading to concerns about prolonged treatment. These potential adverse effects can contribute to patient non-compliance, making it difficult to achieve consistent treatment outcomes and ultimately hindering the overall effectiveness of managing nodular prurigo. As a result, the side effects associated with current treatments represent a considerable market challenge hindering overall market growth.

• Impeding Regulatory Standards

Regulatory hurdles pose a significant challenge in the development of new therapies for nodular prurigo, particularly for biologics and novel treatments that require rigorous approval processes. Regulatory agencies, such as the U.S. FDA and the European Medicines Agency (EMA), mandate comprehensive clinical trials to ensure the safety and efficacy of new drugs, which can significantly extend development timelines and increase costs. For example, Dupilumab, a biologic used in treating several inflammatory skin conditions, faced extensive clinical testing before receiving approval for its expanded use in prurigo nodularis. These stringent requirements, while crucial for patient safety, can delay the introduction of innovative treatments, slowing market entry and limiting immediate access for patients in need. Such regulatory burden can stifle innovation and disincentivize pharmaceutical companies from investing in new treatments, hampering the market growth for nodular prurigo.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Nodular Prurigo Market Scope

The market is segmented on the basis of product, end-user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Antihistamines
• Capsaicin Cream
• Corticosteroids
• Emollients
• Others

End-User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channels

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Nodular Prurigo Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, product, end-user, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has experienced robust growth in the nodular prurigo market throughout the forecast period, driven by the presence of major market players that enhance competition and innovation. The region's significant increase in research and development expenditure has facilitated advancements in treatment options, addressing unmet medical needs in dermatological care. Additionally, the high incidence of dermatological diseases in North America has underscored the urgent demand for effective therapies, further fueling market expansion and product innovation in this sector.

Asia-Pacific region dominates the nodular prurigo market, driven by the rising prevalence of prurigo nodularis and the emergence of numerous major regional companies contributing to market growth. The increasing burden of chronic diseases among the aging population has heightened the demand for effective dermatological treatments, prompting greater investment in research and development. Additionally, improved healthcare infrastructure and a growing awareness of skin disorders are further enhancing the industry landscape in this region, positioning it for sustained growth in the coming years.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Nodular Prurigo Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Nodular Prurigo Market Leaders Operating in the Market Are:

• Johnson & Johnson Services, Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd (Israel)
• Pfizer Inc (U.S.)
• Hikma Pharmaceuticals PLC (U.K.)
• Takeda Pharmaceutical Company Limited (Japan)
• Bayer AG (Germany)
• Merck & Co., Inc. (U.S.)
• Sanofi (France)
• GSK plc (U.K.)
• Bristol-Myers Squibb Company  (U.S.)
• Galderma Laboratories, L.P. (U.S.)
• Mayne Pharma Group Limited (Australia)
• VYNE Therapeutics Inc. (U.S.)
• Trevi Therapeutics (U.S.)

Latest Developments in Nodular Prurigo Market

• In Febrary 2024, SK Chemicals launched Nose-R soft cap, a third-generation antihistamine formulated with fexofenadine, aimed at providing effective relief from allergic rhinitis while minimizing drowsiness. This innovative treatment offers a significant advantage over first-generation antihistamines, allowing patients to manage their allergy symptoms without experiencing sedation
• In February 2024, Galderma announced that the U.S. FDA had granted approval for its Biologics License Applications for nemolizumab, which is indicated for the treatment of prurigo nodularis and for adolescents and adults with moderate to severe atopic dermatitis
• 2023년 2월, 화이자는 제약 출시의 야심찬 파이프라인 계획을 발표했으며, 회사는 향후 18개월 내에 19개의 신약을 출시할 예정입니다. 이 전략적 이니셔티브는 종양학, 면역학, 희귀 질환을 포함한 다양한 치료 분야에서 혁신과 충족되지 않은 의료적 요구 해결에 대한 화이자의 헌신을 강조합니다.
• 2023년 6월, Neogen Corporation은 스콤브로이드 중독을 일으킬 수 있는 특정 어류의 히스타민 수치를 감지하는 두 가지 새로운 검정법을 설계하여 출시했습니다. 히스타민은 신체에서 보호 역할을 하지만, 때때로 알레르기 반응을 유발할 수 있기 때문에 항히스타민제가 그 효과를 상쇄하는 데 사용됩니다.
• 2023년 6월, 노바티스는 워싱턴주 시애틀에 본사를 둔 임상 단계의 바이오제약 회사인 Chinook Therapeutics를 인수하기로 합의했다고 발표했습니다. Chinook은 희귀하고 심각한 만성 신장 질환에 대한 두 가지 고가치 후기 단계 치료법을 개발하고 있습니다. 표준 마감 조건에 따라 진행되는 이 인수는 혁신적인 의약품에 집중하려는 노바티스의 전략과 완벽하게 일치합니다. 특히 노바티스의 신장 포트폴리오를 크게 강화하고 기존 파이프라인을 보완할 것입니다.

SKU-62798